Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome

Diabetes

Volumn 52, Issue 3, 2003, Pages 803-811

  Watts, Gerald F ^a,c   Barrett, P Hugh R ^a   Ji, Juying ^a   Serone, Adrian P ^b   Chan, Dick C ^a   Croft, Kevin D ^a   Loehrer, Franziska ^b   Johnson, Anthony G ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

ApoAI, apolipoprotein AI; ApoB, apolipoprotein B 100; CETP, cholesteryl; Ester transfer protein; FCR, fractional catabolic rate; GCMS, gas chromatography; HMG, hydroxymethylglutaryl; HOMA, homeostasis model assessment; IDL, intermediate density lipoprotein

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEUCINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; TRIACYLGLYCEROL BLOOD LEVEL; TURNOVER TIME;

ADULT; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIET; DOUBLE-BLIND METHOD; HEPTANOIC ACIDS; HUMANS; INSULIN; KINETICS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, IDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PLACEBOS; PROCETOFEN; PYRROLES; TRIGLYCERIDES;

EID: 0037339775     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.3.803     Document Type: Article

References (50)

1. Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 106:453-458, 2000
2. Packard CJ: Understanding coronary heart disease as a consequence of defective regulation of apolipoprotein B metabolism. Curr Opin Lipidol 10:237-244, 1999
3. Von Ekardstein A, Nofer J-R, Assmann G: High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21:13-27, 2001
4. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100:1134-1146, 1999
5. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10, 1997
6. Roith D, Zick Y: Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 24:588-597, 2001
7. Lewis GF: Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 8:146-153, 1997
8. Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis on the liver. J Clin Invest 109:1125-1131, 2002
9. Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PHR: Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocinol Metab 84:2854-2861, 1999
10. Brinton EA, Eisenberg S, Breslow JL: Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size: effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 14:707-720, 1994
11. Pietzsch J, Julius U, Nitzsche S, Hanefield M: In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose intolerance. Diabetes 47:1928-1934, 1998
12. Grundy SM: Statin trials and goals of cholesterol-lowering therapy. Circulation 97:1436-1439, 1998
13. Aguilar-Salinas CA, Barrett H, Schonfeld G: Metabolic modes of action of the statins in the hyperlipoproteinemias. Atherosclerosis 41:203-207, 1998
14. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial: the Care Investigators. Circulation 98:2513-2519, 1998
15. Bilheimer DW, Grundy SM, Brown MS Goldstein JL: Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci 80:4124-4128, 1983
16. Watts GF, Naomova RP, Kelly JM, Riches FM, Croft KD, Thompson GR: Inhibition of cholesterogenesis decreases the hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 273:462-470, 1997
17. Guerin M, Lassel T, Le Goff W, Farnier M, Chapman MJ: Action of atorvastatin on combined hyperlipidemia: preferential reduction of cholesterol ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20:189-197, 2000
18. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B: Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 107:1423-1432, 2001
19. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088-2093, 1998
20. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 3411:410-418, 1999
21. Watts GF, Dimmitt SB: Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 10:561-574, 1999
22. Diabetes Atherosclerosis Intervention Study (DAIS) Investigators: Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes. Lancet 357:905-910, 2001
23. Schoonjans K, Peinado-Onsurbe L, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J: PPAR alpha and PPAR gamma activators direct a distinct tissue-specific transcriptional response via PPRE in the lipoprotein lipase gene. EMBO J 15:5336-5348, 1996
24. Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, Fruchart JC, Laudet V, Staels B: The nuclear receptors peroxisome proliferator-activated receptor x and Rev-erbx mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 273:25713-25720, 1998
25. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96:741-750, 1995
26. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Med 7:53-58, 2001
27. Hertz R, Bishara-Shieban J: Mode of action of peroxisome proliferators as hypolipidemic drug, suppression of apolipoprotein C-III. J Biol Chem 270:13470-13475, 1995
28. Frost RJA, Otto C, Geiss C, Schwandt P, Parhofer KG: Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes melltius with mixed hyperlipoproteinemia. Am J Cardiol 87:44-48, 2001
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
30. Chan DC, Watts GF, Barrett PHR, Berlin LJ, Redgrave TG, Mori TA: Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 in insulin-resistant obese male subjects with dyslipidemia. Diabetes 51:2377-2386, 2002
31. Schaefer EJ, Ordovas JM: Metabolism of apolipoproteins A-I, A-II and A-IV. Meth Enzym 129:420-443, 1986
32. Zech LA, Schaefer EJ, Bronzert TJ, Aamodt RL, Brewer HB Jr: Metabolism of human apolipoproteins A-I and AII: compartmental models. J Lipid Res 24:60-71, 1983
33. Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PH: Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 51:1041-1046, 2002
34. Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Kelly JM, Jackson NC, Sonksen PH: Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes 44:1059-1065, 1995
35. Duvillard L, Pont F, Florentin E, Gambert P, Verges B: Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 152:229-237, 2000
36. Frenais R, Nazih H, Ouguerram K, Maugeais C, Zair Y, Bard JM, Charbonnel B, Magot T, Krempf M: In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type lI diabetes mellitus. J Clin Endocrinol Metab 86:1962-1967, 2001
37. Gaw A, Packard CJ, Murray E, Lindsay GM, Griffin BA, Caslake MJ, Vallance BD, Lorimer AR, Shepherd J: Effects of simvastatin on apo B metabolism and LDL subfraction distribution. Arterioscler Thromb Vasc Biol 13:170-189, 1993
38. Arad Y, Ramakrishnan R, Ginsberg HN: Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidaemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipd Res 31:567-582, 1990
39. Schaefer JR, Schweer H, Ikewaki K, Stracke H, Seyberth HJ, Kaffarnik H, Maisch B, Steinmetz A: Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 144:177-184, 1999
40. f 100-4-00) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest 74:2164-2177, 1984
41. Packard CJ, Clegg RJ, Dominiczak MH, Lorimer AR, Shepherd J: Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoprotein subjects. J Lipid Res 27:930-938, 1986
42. Stewart JM, Packard CJ, Lorimer AR, Boag DE, Shepherd J: Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinemic subjects. Atherosclerosis 44:355-364, 1982
43. Caslake MJ, Packard CJ, Gaw A, Murray E, Griffin BA, Vallance BD, Shepherd J: Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 13:702-711, 1993
44. Saku K, Gartside PS, Hynd BA, Kashyap ML: Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 75:1702-1712, 1985
45. Malmendier CL, Delecroix C: Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis 55:161-169, 1985
46. Huff MW, Burnett JR: 3-Hydroxy-3-methylflutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr Opin Lipidol 8:138-145, 1997
47. Schneider A, Strange EF, Ditschuneit HH, Ditschuneit H: Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients. Atherosclerosis 56:257-262, 1985
48. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ: Fenofibrate reduces plasma cholesterol ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidaemia. Arterioscler Thromb Vasc Biol 16:763-772, 1996
49. Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN: Effects of two different fibric acid derivatives on lipoproteins, cholesterol ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 138:217-225, 1998
50. Ikewaki K, Zech LA, Kindt M, Brewer B Jr, Rader DJ: Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-1:A-II in normolipidemic humans. Arterioscler Thromb Vasc Biol 15:306-312, 1995